68 results about "Endogenous metabolism" patented technology

The present invention relates to novel compounds and formulations thereof which compounds are ligands, e.g., agonists or antagonists, for a metabotropic glutamate receptor or a NAALADase enzyme or both. The present invention also relates to methods of modulating the activity of a metabotropic glutamate receptor or a NAALADase enzyme or both, e.g., in a subject in need thereof, using a compound or formulation of the present invention. The present invention also relates to methods of treating a subject suffering from a chronic or acute disease, malady or condition due at least in part to an abnormality in the activity of an endogenous metabotropic glutamate receptor or a NAALADase enzyme or both, using a compound or formulation of the present invention.

The invention provides a method for evaluating the quality of a Chinese patent medicament by using metabonomics. The method comprises the following steps: 1) according to the indication of traditional Chinese medicines, establishing a corresponding animal model and screening; 2) taking various of samples of the traditional Chinese medicines, and intervening a disease model animal by a corresponding route of administration; 3) collecting a corresponding biological sample and acquiring the metabolism finger-print of the sample; 4) carrying out pattern recognition on the metabolism fingerprints of a normal group and a disease group to obtain a metabolism biomarker group; 5) calculating the similarity of the metabolism biomarker group and the normal group in different administration groups, or carrying out PLS (partial least squares) regression analysis on differential endogenous metabolites, and observing the influence of medicament treatment on the endogenous metabolites; and 6) according to the similarity result or the result of the PLS regression analysis, evaluating the medicaments, wherein the more normal the control group trends to be, the better efficacy of the medicament is.

The invention discloses a test method for characterizing the biological effects of smoke exposure based on metabolomics. The test method adopts the metabolomics analysis method, and the biomarker groups related to the biological effects of smoke exposure are tested in different drug administration groups. The changes between groups are used to characterize the biological responses of experimental animals placed in the smoke exposure environment. The present invention is easy to operate, and evaluates the influence of mainstream smoke on endogenous metabolites in rats, and compares the similarities and differences between the effects of natural herbal added tobacco and ordinary cigarettes on endogenous metabolites, in order to evaluate the harm reduction effect of cigarettes and its associated mechanisms provide a reliable tool.

The invention discloses a method for identifying the varieties of dendrobium huoshanense and dendrobium officinale based on metabonomics. The method comprises the following specific steps: (1) collecting dendrobium samples; (2) preparing dendrobium metabonomics samples; (3) detecting metabolites of the dendrobium samples; and (4) performing metabonomics data processing and analysis. The method provided by the invention has the following advantages: a lot of endogenous metabolite information of dendrobium is acquired by means of metabonomics; among the endogenous metabolites, the characteristic metabolites for identification of dendrobium huoshanense and dendrobium officinale are selected out, and then such two dendrobium varieties are distinguished from each other on the whole; the technical mode is advanced and the experimental result is reliable; and a good means is provided for dendrobium variety identification and dendrobium quality assessment.

The invention discloses a use of endogenous metabolites as markers for predicting the prognosis risk of coronary heart disease or in preparation of a kit for predicting the prognosis risk of coronaryheart disease. The metabolite marker can effectively predict the risk of death and major adverse cardiovascular events (MACE) in patients with coronary heart disease and the risk of cardiac insufficiency, and has the characteristics of specificity, sensitivity, high efficiency and non-invasiveness. After the metabolite marker is used for predicting the prognosis survival rate of patients with coronary heart disease, the AUC is 65% or more. Through combination, the AUC is close to 100% compared with AUC based on the single marker and the prediction effect is good. The method for detecting through the marker has high sensitivity, is convenient and quick and produces accurate and reliable results. The predictive model constructed by the marker can be used for predicting the prognosis risk ofcoronary heart disease, has good predictive effects and high sensitivity, is convenient, rapid and non-invasive and has an important clinical application value.

The invention belongs to the technical field of model establishment and evaluation methods with an aim to solve problems about low flexibility and poor accuracy in an existing model establishment andevaluation method for the nephritic syndrome rats and provides a model establishment and evaluation method for the nephritic syndrome rats. Changes of endogenous metabolites in the urine of terminal products are analyzed by metabolomics, all 1 HNMR spectra are processed through MestReNova software to acquire integral data, statistical analysis of the content of 12 biomarkers is combined with, thechanges of the mean value of the 12 biomarkers in the urine before and after modeling reflect the change trend of the urine metabolite content in the nephritic syndrome rats, and models of nephritic syndrome are evaluated in a targeted manner. Dynamic body contours before and after modeling is reflected comprehensively, flexibly and systematically, rationality and scientific nature of model reproduction are comprehensively reflected, the reliable evaluation method for new drug development and pharmacological research is provided, and the method is efficient, rapid, noninvasive and high in specificity.

The invention relates to a drug screening cell model with NLRP3 (NLR family, pyrin domain containing 3) as a target spot and an application of the drug screening cell model. According to the cell model, a mammalian cell is used as a host, a recombinant plasmid containing an NLRP3 3'-UTR (untranslated region) core sequence and a reporter gene is transfected, and the NLRP3 3'-UTR core sequence is one of SEQ ID 1-9. According to the cell model, the minimum 3'-UTR sequence which can substitute for the NLRP3 mRNA (messenger ribonucleic acid) overall length is found with a 3'-UTR fragment reduction method, the sequence is connected with the reporter gene, and then the connected recombinant plasmid is transfected into an HCT116 cell strain to form a stable-expression cell strain, then endogenous metabolite and natural compounds to be screened are added, the expression level of the reporter gene is determined, and meanwhile, positive and negative control groups are established, so that the activity of substances to be screened are evaluated, and a sensitive and effective natural innovative drug screening method applicable to high-flux anti-infective drugs is provided.

The invention discloses a method for screening myocardial ischemia resisting pharmacodynamic material basis of yang exhaustion treating decoction. The method comprises the following steps: 1, determining myocardial ischemia resisting endogenous metabolin of the yang exhaustion treating decoction and measuring the peak area; 2, determining in-vivo migration constituents in the yang exhaustion treating decoction and measuring the peak area; 3, performing correlation analysis on the peak area of the myocardial ischemia resisting endogenous metabolin of the yang exhaustion treating decoction and the peak area of the in-vivo migration constituents in the yang exhaustion treating decoction and screening out myocardial ischemia resisting pharmacodynamic material basis of the yang exhaustion treating decoction. The method disclosed by the invention is based on isoproterenol-induced rat myocardial ischemia model; an ultrahigh performance liquid chromatography-quadrupole rod-flight time mass spectrum non-targeted metabonomic technology and a targeted metabonomic technology based on an ultrahigh performance liquid chromatography-triple quadrupole rod mass spectrum are utilized to screen out 12 kinds of myocardial ischemia resisting pharmacodynamic material basis of the yang exhaustion treating decoction; thus, accuracy of the myocardial ischemia resisting pharmacodynamic material basis ofthe yang exhaustion treating decoction is improved, a screening period is shortened, and screening consumption cost is reduced.

The invention discloses an endogenous metabolic small molecular marker for indicating a healthy aging key pathway and application. The number of the endogenous metabolic small molecules is 155. The key pathway is totally 30. The invention provides a new endogenous small molecule marker for indicating the key pathways for blood health and aging for the first time, and the change of the small molecules can be measured to comprehensively evaluate the change of pathways related to health and aging in a human body, thereby providing support for subsequent intervention and response.

The invention discloses an early liver cancer rat model construction and evaluation method, and belongs to the technical field of model construction and evaluation methods. The scheme of the inventionmainly solves the problems of poor accuracy, low sensitivity, time waste and energy waste of a current early liver cancer rat model construction and evaluation method. The scheme of the invention adopts a metabonomics technology, and analyzes changes in endogenous metabolites in urine, the end product of the body before and after modeling, to obtain a dynamic trajectory map of the metabolic profile of the pathological process. In addition, all nuclear magnetic resonance spectrums are processed by using MestReNova software to obtain integral data, the content of 19 biomarkers is combined for statistical analysis, and results show that the change of the integral mean value of the 19 biomarkers in the urine before and after modeling reflects the change trend of the urine metabolic process ofrats with liver cancer. The method of the invention provides a detection method that is simple to obtain specimens, and is more economical, safe and effective, and provides a high-sensitivity, high-throughput, non-invasive, and highly-specific evaluation method for new drug research and development and pharmacological research.

The invention discloses a metabolism transformation Bacillus subtilis biotransformed cell. The preparation method comprises: carrying out recombinant over-expression to obtain a L-glutamic acid oxidase, carrying out metabolism engineering transformation on the endogenous glutamic acid decomposition pathway of Bacillus subtilis, and finally transforming the glutamic acid transport pathway of Bacillus subtilis to prepare the Bacillus subtilis biotransformed cell, ie., the recombinant Bacillus subtilis. According to the present invention, the experimental basis is provided for the construction and the improvement of the whole cell transformation system involved in cellular endogenous metabolism, and the reference is provided for the production of alpha-ketoglutaric acid through the efficient whole cell transformation of L-glutamic acid with Bacillus subtilis.

The invention discloses a cold-coagulation-blood-stasis-syndrome-resistant differential metabolite metabolic pathway and study method of a Chinese angelica-based cold-coagulation blood-stasis treatment decoction. The method comprises: detecting and analyzing endogenous metabolites changed at different time points after cold-coagulation blood-stasis symptoms forming of a female rat under an ice-water bath and epinephrine induction and Chinese angelica-based cold-coagulation blood-stasis treatment decoction intervention by using an ultra-high performance liquid chromatography tandem mass spectrometry so as to obtain a fingerprint spectrum; with a multivariate variable statistical analysis method, carrying out screening from a plurality of variables and identifying 21 significantly changed metabolites; and enriching eight metabolic pathways related to different development stages of the cold-coagulation blood-stasis symptom by using ametaboanalyst open-source online metabonomics analysiswebsite. According to the invention, the related metabolic changes in the occurrence and development process of the old-coagulation blood-stasis symptoms and the treatment process of the Chinese angelica-based cold-coagulation blood-stasis treatment decoction are studied by using a dynamic analysis method; the disease occurrence and development mechanisms at different time points can be revealed;and the abnormal metabolic network regulated and controlled by medicines in the treatment process can be clarified.

The invention discloses a determination method of the potency of a traditional Chinese medicine zedoary turmeric oil by using metabolomics. The method comprises the steps that: an unilateral ureteral obstruction induced renal interstitial fibrosis model is adopted, an animal modeling is carried out; processing and sampling are carried out after animal modeling is carried out for 3 days, 7 days, 14 days, 21 days, and 28 days; animal kidney tissues are fetched; kidney tissue pathological changes are observed by using an optical microscope; serum samples are prepared, and 1H NMR spectral data is obtained; NMR data processing and pattern recognition analysis are carried out; and analysis is carried out by using SPSS13.0 software. According to the invention, information of large amount of endogenous metabolites in bodies can be obtained with the metabolomic technology, and metabolite changes of potencies of various effective components in zedoary turmeric oil upon various targets can be screened. Therefore, the potency of zedoary turmeric oil can be comprehensively evaluated. The invention provides an excellent method for evaluating zedoary turmeric oil potency.

The invention belongs to the technical field of biological analysis and detection, and relates to an ion strength virtual correction and quantitative mass spectrum imaging analysis method of drugs, which can be used for exploring the accurate content of drug molecules at different spatial positions in a living body. According to the method, isotope labeled drugs are not needed to be used as internal standards, endogenous metabolite ions of each mass spectrum image acquisition pixel point are used as natural internal standards, a multiple regression prediction model of the endogenous metaboliteions-drug relative matrix effect is established, virtual correction of the biological tissue specific matrix effect is achieved, and quantitative calculation of drug content in any area in a whole biological tissue sample is completed through a standard curve established by a standard reference sample. The invention provides an intuitive and visual quantitative imaging method for quickly acquiring absorption, distribution, metabolism and excretion information of candidate drugs in a body, predicting potential toxic and side effects and the like.

The invention discloses an anti-static polyvinyl alcohol fruit and vegetable fresh-keeping film. The anti-static polyvinyl alcohol fruit and vegetable fresh-keeping film is characterized by being prepared from the following raw materials: appropriate amounts of camellia seed, mint leaf, rhizoma zingiberis, pine twig, clove, acetone, anhydrous sodium sulfate, zeolite, sodium nitrate solution, silver nitrate solution, sodium hexametaphosphate, hydroxyethyl acrylate, acrylic acid, absolute ethyl alcohol, azodiisobutyronitrile, lauryl mercaptan, polyvinyl alcohol, vinyl acetate, ammonium persulfate solution, octadecyl imidazoline, fatty alcohol-polyoxyethylene ether, dodecyl potassium phosphate, and deionized water. The anti-static polyvinyl alcohol fruit and vegetable fresh-keeping film of the invention is good in mechanical performance, stable in structure, good in air permeability, and good in antibacterial action, and can slow down endogenous metabolism aging of fruits and vegetables and spoilage caused by exogenous microorganisms, thus greatly prolonging the length for preservation and effectively keeping the quality of the fruits and vegetables.

The invention belongs to the technical field of evaluation methods of models, and particularly relates to construction and evaluation methods of a blood deficiency mouse model. The construction and evaluation methods mainly solve the technical problems that an existing evaluation method of a blood deficiency model is low in precision and poor in specificity. According to the construction and evaluation methods of the blood deficiency model, a metabonomic technology is adopted, the change of endogenous metabolites in the spleen organs of mice of a blank control group and a model group is analyzed, all mass spectrum spectrograms are processed through CD software to obtain integral data, then in combination with the content of 15 biomarkers, statistical analysis is made to the integral mean value change tendency of biomarkers in the spleen organs of the mice of the blank control group and the model group, so that the change tendency of the content of the metabolites of the spleen organs of the blood deficiency mice is obtained, and thus the blood deficiency mouse model is evaluated with pertinence. By means of the construction and evaluation methods, the rationality and scientificityof model replication are reflected, the profiles of mouse bodies of the blank control group and the model group are systematically and comprehensively shown, the methods have the advantages of being comprehensive, systematic, efficient and high in specificity, and a reliable evaluation method is provided for new drug research and development and pharmacological research.

The present invention establishes a simultaneous quantification method for mouse plasma based on UPLC-HRMS, in which the method targets astragaloside IV and cycloxanthine that is the main metabolite of astragaloside IV. The quantitative time of the method is 3 mins, digoxin is used as an internal standard, and only 20 [mu]L of mouse plasma is needed, thus having the advantages of rapidity, high sensitivity and strong specificity. After being precipitated by the protein, the sample is filtered by dephospholipidation plate, which effectively reduces the matrix effect of endogenous metabolites ofphospholipids in plasma on the analyte. Ultra-high performance C18 column is used as the analytical column to detect two kinds of analytes and internal standards in the electrospray ion source positive ion selective ion monitoring mode. The linear range of the two analytes is 1-200ng/mL, the intra-day and inter-day precision is <=8.6%, and the precision is <=8.8%, which indicates that the methodhas good precision and accuracy. The method for simultaneously quantitatively detecting astragaloside-IV and cycloxanthine in mouse plasma was successfully applied to the pharmacokinetic study of astragaloside IV mice.